Why Charles River (CRL) Is Up 9.1% After Naming Long‑Time Insider Birgit Girshick CEO

Simply Wall St.01-11

Charles River Laboratories International announced that long‑time Chair, President and CEO James C. Foster will retire in May 2026, with current Chief Operating Officer Birgit Girshick appointed as ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2602351552?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","is_english":true,"pubTime":"2026-01-11 22:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602351552","market":"sg","top_or_hot":-1,"title":"Why Charles River (CRL) Is Up 9.1% After Naming Long‑Time Insider Birgit Girshick CEO","media":"Simply Wall St.","content":"<div>\n<p>Charles River Laboratories International announced that long‑time Chair, President and CEO James C. Foster will retire in May 2026, with current Chief Operating Officer Birgit Girshick appointed as ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-crl/charles-river-laboratories-international/news/why-charles-river-crl-is-up-91-after-naming-longtime-insider\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Charles River (CRL) Is Up 9.1% After Naming Long‑Time Insider Birgit Girshick CEO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Charles River (CRL) Is Up 9.1% After Naming Long‑Time Insider Birgit Girshick CEO\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-11 22:14 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-crl/charles-river-laboratories-international/news/why-charles-river-crl-is-up-91-after-naming-longtime-insider><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Charles River Laboratories International announced that long‑time Chair, President and CEO James C. Foster will retire in May 2026, with current Chief Operating Officer Birgit Girshick appointed as ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-crl/charles-river-laboratories-international/news/why-charles-river-crl-is-up-91-after-naming-longtime-insider\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-crl/charles-river-laboratories-international/news/why-charles-river-crl-is-up-91-after-naming-longtime-insider","article_id":"2602351552","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-crl/charles-river-laboratories-international/news/why-charles-river-crl-is-up-91-after-naming-longtime-insider","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2602351552","pubTimestamp":1768140871,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Charles River Laboratories International announced that long‑time Chair, President and CEO James C. Foster will retire in May 2026, with current Chief Operating Officer Birgit Girshick appointed as his successor and nominated to join the Board, while Foster remains as a non‑executive Director and the Chair and CEO roles are separated.\nThis transition caps Foster’s 50‑year tenure in which Charles River evolved from a niche research models business into a global preclinical contract research...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","IE00BFMHRM44.USD":"NEUBERGER BERMAN GLOBAL EQUITY MEGATRENDS \"A\" (USD) ACC","LU1815336091.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AUP\" (USD) INC","LU0757428866.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AE\" (USD) ACC","CRL.AU":"Comet Resources Ltd","CRL":"查尔斯河","BK4121":"生命科学工具和服务","BK7095":"多种金属与采矿","BK4530":"医药外包概念","LU0128526141.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" ACC","LU0390134368.USD":"FRANKLIN GLOBAL GROWTH \"A\" (USD) ACC","LU0029874061.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" YDIS INC","BK4588":"碎股"},"translate_title":"为什么Charles River(CRL)在任命长期内部人士Birgit Girshick为首席执行官后股价上涨9.1%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRL.AU":1.5,"CRL":1.5},"content_text":"Charles River Laboratories International announced that long‑time Chair, President and CEO James C. Foster will retire in May 2026, with current Chief Operating Officer Birgit Girshick appointed as his successor and nominated to join the Board, while Foster remains as a non‑executive Director and the Chair and CEO roles are separated. This transition caps Foster’s 50‑year tenure in which Charles River evolved from a niche research models business into a global preclinical contract research organization generating over 80% of its revenue from services, while Girshick brings more than 35 years of internal operational leadership across nearly all major business lines. We’ll now examine how elevating long‑serving COO Birgit Girshick to CEO reshapes Charles River’s existing investment narrative and risk profile. We've found 12 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.AdvertisementCharles River Laboratories International Investment Narrative RecapTo own Charles River Laboratories, you need to believe its position in outsourced preclinical research can translate a complex, service heavy model into improving profitability despite recent revenue softness, biotech funding uncertainty and competition. The CEO succession to long serving COO Birgit Girshick appears thoughtfully staged and, by itself, does not materially change the near term focus on converting backlog, stabilizing DSA demand and containing margin pressure from pricing and cancellations. The May 2025 announcement of a wide ranging strategic review, coupled with Elliott Investment Management joining as a cooperating investor, is the clearest recent signal that Charles River’s board is already probing options to improve growth, returns and capital allocation. Against that backdrop, the Girshick transition looks more like the governance and leadership continuity piece of a broader reset than a standalone catalyst, with execution on cost savings and organic demand recovery still doing most of the heavy lifting. But even with this orderly succession plan, investors should be aware that rising cancellations and a book to bill below 1x could... Read the full narrative on Charles River Laboratories International (it's free!)Charles River Laboratories International's narrative projects $4.4 billion revenue and $483.2 million earnings by 2028. This requires 2.8% yearly revenue growth and a $552.4 million earnings increase from -$69.2 million today.Uncover how Charles River Laboratories International's forecasts yield a $188.93 fair value, a 14% downside to its current price.Exploring Other PerspectivesCRL 1-Year Stock Price Chart Two fair value estimates from the Simply Wall St Community span roughly US$188.93 to US$251.05 per share, showing how far apart individual expectations can be. You should weigh these against the current dependence on backlog conversion amid softer organic bookings, which could influence how quickly any perceived mispricing is resolved.Explore 2 other fair value estimates on Charles River Laboratories International - why the stock might be worth as much as 14% more than the current price!Build Your Own Charles River Laboratories International NarrativeDisagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.A great starting point for your Charles River Laboratories International research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.Our free Charles River Laboratories International research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Charles River Laboratories International's overall financial health at a glance.Contemplating Other Strategies?Our daily scans reveal stocks with breakout potential. Don't miss this chance:AI is about to change healthcare. These 30 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.This technology could replace computers: discover 29 stocks that are working to make quantum computing a reality.The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2602351552","isCrawlerRequest":true}